Drospirenone Acid (sodium salt) is chemically Sodium 3-((4aR,4bS,6aS,7S,7aS,8aS,8bS,8cR,8dR,9aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-3,4,4a,4b,5,6,6a,7,7a,8,8a,8b,8c,8d,9,9a-hexadecahydro-2H-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-7-yl)propanoate. Drospirenone Acid (sodium salt) is supplied with detailed characterization data compliant with regulatory guideline. Drospirenone Acid (sodium salt) can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Drospirenone.
关键字: 医药对照品;
祥根生物医药于2008年12月成立,是一家集药物研发、生产、销售的创新型医药高科技企业,荣获“国家高新技术企业”和“博士后实践创新基地”等称号。祥根生物医药拥有药物成分标准物质、关键中间体、原料药与药品进出口全产业链平台。祥根是众多全球知名标准品(Aozeal/USP/EP/LGC/Bachem/TLC/TRC/意大利试剂等)和原料药(INKE/Bachem/瑞迪/意迪那等)总代理和授权代理商,处于行业领先水平。
祥根生物医药拥有一个尊重人才、重视绩效、持续创新的平台。 研发团队由多名海外高层次人才领衔,研发人员50余人;获得相关发明专利30余项。祥根生物医药的企业责任是:回报员工、回报合作伙伴、回报社会;企业愿景是:提升药品质量,保护人类健康。